Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years With Attention-deficit/Hyperactivity Disorder
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Amfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Tris Pharma
- 17 Jan 2019 According to a Tris Pharma media release, data from the trial will be presented at the 2019 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
- 12 Nov 2018 According to a Tris Pharma media release, data from this trial was presented at the 2018 Neuroscience Education Institute (NEI) Congress.
- 07 Aug 2018 New trial record